Ivermectin for COVID-19 : promising but not yet conclusive
Date
2021-03
Journal Title
Journal ISSN
Volume Title
Publisher
Health & Medical Publishing Group
Abstract
Ivermectin has been proposed as a potential definitive
and prophylactic treatment for COVID-19.[1] Ivermectin is an
anthelmintic drug that is usually indicated for filarial and resistant
scabies infections, but has been shown to have antiviral activity and
anti-inflammatory activity in vitro.[2,3] Ivermectin has the potential to
be a promising directed therapy in the drug armamentarium against
COVID-19, as it has been shown to have in vitro activity against
SARS-CoV-2.[4]
Several randomised controlled trials (RCTs) and observational
studies have reported on the effectiveness and safety outcomes of
ivermectin in COVID-19.[1,5] These data are very promising, showing
large treatment effects and acceptable adverse effect profiles for
ivermectin against COVID-19, especially when combined in metaanalyses.
Description
CITATION: Van Rensburg, R. et al. 2021. Ivermectin for COVID-19 : promising but not yet conclusive. South African Medical Journal, 111(3):188, doi:10.7196/SAMJ.2021.v111i3.15522.
The original publication is available at http://www.samj.org.za
The original publication is available at http://www.samj.org.za
Keywords
Anthelminthics, Drug development, Drugs -- Effectiveness, Ivermectin, Anthelmintics
Citation
Van Rensburg, R. et al. 2021. Ivermectin for COVID-19 : promising but not yet conclusive. South African Medical Journal, 111(3):188, doi:10.7196/SAMJ.2021.v111i3.15522.